FDA approves an updated Ibtrozi label for locally advanced or metastatic ROS1-positive NSCLC, reflecting nearly four years of response data.
|Articles|April 4, 2022
How Do I Find Me Again?
Advertisement
It’s completely normal to feel disoriented and detached from our old lives and original selves after anything as life-altering as a breast cancer diagnosis. Learn how to connect deeply to what matters to you now and what has always mattered to you–threads that will help weave together the “yous” from all stages of your life.
Advertisement
Related to this article
Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
At three years, 69% of patients treated with Imfinzi and chemotherapy around surgery were alive, compared with 62% of patients treated with chemotherapy alone.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.
A powerful reflection on finding hope, healing and meaning through life’s challenges, inspired by the lessons and beauty found in the sea.
Advertisement
Advertisement
Trending on CURE
1
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
2
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
3
Top 3 Takeaways From WCLC 2026 That Patients Should Know
4
A Gift from the Sea
5